European regulatory authority raises safety concern w.r.t use of Fluoroquinolones derivatives like Norfloxacin and Moxifloxacin

The European regulatory agency has raised safety concern w.r.t use of Fluoroquinolones derivatives like Norfloxacin and Moxifloxacin. Finalising a review of the safety of Moxifloxacin-containing medicines for oral use, the European Medicines Agency (EMEA) has concluded that these medicines should only be prescribed in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and pneumonia when other antibiotics cannot be used or have failed. The European Medicines Agency has recommended restricting the use of oral Norfloxacin containing medicines in urinary infections. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the marketing authorisations for oral Norfloxacin-containing medicines, when used in the treatment of acute or chronic complicated pyelonephritis (kidney infection), should be withdrawn because the benefits of these medicines do not outweigh their risks in this indication.